Department of General Surgery.
Department of Emergency Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Medicine (Baltimore). 2021 Apr 2;100(13):e25308. doi: 10.1097/MD.0000000000025308.
Since its introduction in 1991, laparoscopic splenectomy (LS) has become the gold standard in elective spleen surgery in many centres. However, there still lack the report of long-term outcomes of LS with the large-scale cases. The aim of the present study was to analyze the short- and long-term outcomes of LS in a single institution over 16 years, and to compare the perioperative outcomes of totally laparoscopic splenectomy (TLS) and hand-assisted laparoscopic splenectomy (HALS) for splenomegaly.Between November 2002 and December 2018, 486 consecutive patients undergoing elective LS were enrolled in this study, including 222 TLS and 264 HALS. The intraoperative, postoperative, and follow-up data were retrospectively analyzed.The 5 most common indications were hypersplenism (71.0%), immune thrombocytopenia (14.8%), splenic benign tumor (4.5%), splenic cyst (2.9%), and splenic malignant tumor (2.9%). The mean operative time, intraoperative blood loss, and length of stay were 149.4 ± 63.3 minutes, 230.1 ± 225.1 mL, and 6.7 ± 3.2 days, respectively. The morbidity, mortality, reoperation, and conversion rate were 23.0%, 0, 0.4%, and 1.9%, respectively. Portal vein system thrombosis (PVST) was the most frequent complication with an incidence of 19.8%. The incidence of PVST in HALS was higher than that in TLS (23.9% vs 14.9%, P = .013). Compared with TLS, HALS had a shorter operative time (P = .000), lower intraoperative blood loss (P = .000), comparable conversion rate (P = .271), and morbidity (P = .922) for splenomegaly > 17.0 cm. During the follow-up period, the overall respond rate for immune thrombocytopenia was 77.8%, and the esophagogastric variceal bleeding rate was 6.9% in 320 patients with hypersplenism secondary to hepatic cirrhosis.LS is a safe, feasible, and effective procedure with satisfactory short- and long-term outcomes. HALS is a reasonable technique in patients with massive spleens.
自 1991 年引入以来,腹腔镜脾切除术(LS)已成为许多中心择期脾手术的金标准。然而,对于 LS 的长期结果仍缺乏大规模病例的报告。本研究的目的是分析一家机构 16 年来 LS 的短期和长期结果,并比较完全腹腔镜脾切除术(TLS)和手助腹腔镜脾切除术(HALS)治疗脾肿大的围手术期结果。
2002 年 11 月至 2018 年 12 月,连续 486 例接受 LS 的患者纳入本研究,其中 222 例行 TLS,264 例行 HALS。回顾性分析了术中、术后和随访资料。
5 种最常见的适应证为:脾功能亢进(71.0%)、免疫性血小板减少症(14.8%)、脾良性肿瘤(4.5%)、脾囊肿(2.9%)和脾恶性肿瘤(2.9%)。手术时间、术中出血量和住院时间分别为 149.4±63.3min、230.1±225.1mL 和 6.7±3.2d。发病率、死亡率、再次手术和中转率分别为 23.0%、0、0.4%和 1.9%。门静脉系统血栓形成(PVST)是最常见的并发症,发生率为 19.8%。HALS 中 PVST 的发生率高于 TLS(23.9%比 14.9%,P=0.013)。与 TLS 相比,HALS 的手术时间更短(P=0.000),术中出血量更少(P=0.000),中转率相当(P=0.271),脾肿大>17.0cm 的发病率更低(P=0.922)。在随访期间,320 例肝硬化继发脾功能亢进患者的免疫性血小板减少症总体缓解率为 77.8%,食管胃静脉曲张出血率为 6.9%。
LS 是一种安全、可行、有效的手术,具有满意的短期和长期效果。HALS 是治疗巨脾的一种合理技术。